SG10201709164UA - Antibodies Targeting B-Cell Receptor Complex Membrane Bound IgM and Uses Thereof - Google Patents

Antibodies Targeting B-Cell Receptor Complex Membrane Bound IgM and Uses Thereof

Info

Publication number
SG10201709164UA
SG10201709164UA SG10201709164UA SG10201709164UA SG10201709164UA SG 10201709164U A SG10201709164U A SG 10201709164UA SG 10201709164U A SG10201709164U A SG 10201709164UA SG 10201709164U A SG10201709164U A SG 10201709164UA SG 10201709164U A SG10201709164U A SG 10201709164UA
Authority
SG
Singapore
Prior art keywords
cell receptor
receptor complex
membrane bound
antibodies targeting
complex membrane
Prior art date
Application number
SG10201709164UA
Inventor
Welt Sydney
Kostyal David
S Welt Rachel
Raymond Virginia
A Welt Jonathan
Original Assignee
Welt Bio-Molecular Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welt Bio-Molecular Pharmaceutical Llc filed Critical Welt Bio-Molecular Pharmaceutical Llc
Publication of SG10201709164UA publication Critical patent/SG10201709164UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201709164UA 2013-12-03 2014-12-01 Antibodies Targeting B-Cell Receptor Complex Membrane Bound IgM and Uses Thereof SG10201709164UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361911186P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
SG10201709164UA true SG10201709164UA (en) 2017-12-28

Family

ID=53274268

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201709164UA SG10201709164UA (en) 2013-12-03 2014-12-01 Antibodies Targeting B-Cell Receptor Complex Membrane Bound IgM and Uses Thereof

Country Status (9)

Country Link
US (2) US9926381B2 (en)
EP (1) EP3077010B1 (en)
JP (1) JP6535668B2 (en)
CN (1) CN106456809B (en)
AU (2) AU2014357450B2 (en)
CA (1) CA2931779C (en)
IL (1) IL245880B (en)
SG (1) SG10201709164UA (en)
WO (1) WO2015084736A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210106494A (en) * 2018-12-20 2021-08-30 아바 라이프사이언스 게엠베하 How to Select a Biological Binding Molecule

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004005A1 (en) 1989-09-15 1991-04-04 Akzo N.V. Compartmentalized container for a plurality of small articles
AU639719B2 (en) * 1989-09-15 1993-08-05 Tanox Biosystems, Inc. Treatment of autoimmune disease
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2007131129A2 (en) * 2006-05-03 2007-11-15 Guthrie Foundation For Education & Research Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
PL2064325T3 (en) * 2006-09-01 2012-05-31 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
SG176476A1 (en) * 2006-11-02 2011-12-29 Daniel J Capon Hybrid immunoglobulins with moving parts
EP1972640A1 (en) * 2007-03-23 2008-09-24 Biomay AG Apoptosis inducing antibodies
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
US9540657B2 (en) * 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides

Also Published As

Publication number Publication date
CN106456809A (en) 2017-02-22
EP3077010A2 (en) 2016-10-12
US10227419B2 (en) 2019-03-12
US20160304625A1 (en) 2016-10-20
AU2019229346A1 (en) 2019-10-03
WO2015084736A3 (en) 2016-01-21
JP2016540504A (en) 2016-12-28
CN106456809B (en) 2020-02-07
JP6535668B2 (en) 2019-06-26
CA2931779A1 (en) 2015-06-11
US20180186895A1 (en) 2018-07-05
AU2014357450B2 (en) 2019-10-03
AU2014357450A1 (en) 2016-07-14
WO2015084736A4 (en) 2016-02-25
IL245880B (en) 2020-09-30
EP3077010A4 (en) 2017-08-02
WO2015084736A2 (en) 2015-06-11
EP3077010B1 (en) 2020-04-01
US9926381B2 (en) 2018-03-27
CA2931779C (en) 2023-04-25
IL245880A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
HK1212728A1 (en) Multi-chain chimeric antigen receptor and uses thereof
HK1222186A1 (en) Chimeric antigen receptor
HK1222678A1 (en) Cd19 specific chimeric antigen receptor and uses thereof cd19
EP3083964A4 (en) Human mesothelin chimeric antigen receptors and uses thereof
ZA201500457B (en) Anti-kit antibodies and uses thereof
EP2830660A4 (en) Anti-sema4d antibodies and epitopes
HRP20180664T1 (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
HK1223950A1 (en) Monoclonal olfml-3 antibodies and uses thereof olfml-3
IL245880B (en) Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof
HK1210182A1 (en) Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr)
EP2881467A4 (en) Monoclonal antibody against human midkine
ZA201508068B (en) Cd19 specific chimeric antigen receptor and uses thereof